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Proteinengineeringprovidesanopportunitytogeneratenewimmunogenswithdesiredfeatures.Previously,wehavedemonstrated
that hamster polyomavirus major capsid protein VP1-derived virus-like particles (VLPs) are highly immunogenic and can be
employed for the insertion of foreign epitopes at certain surface-exposed positions. In the current study, we have designed
pseudotype VLPs consisting of an intact VP1 protein and VP2 protein fused with the target antigen—cellular marker p16INK4A—at
its N terminus. Both proteins coexpressed in yeast were self-assembled to pseudotype VLPs harbouring the inserted antigen on
the surface. The pseudotype VLPs were used for generation of antibodies against p16INK4A that represents a potential biomarker
for cells transformed by high-risk human papillomavirus (HPV). The pseudotype VLPs induced in immunized mice a strong
immune response against the target antigen. The antisera raised against pseudotype VLPs showed speciﬁc immunostaining of
p16INK4A protein in malignant cervical tissue. Spleen cells of the immunized mice were used to generate monoclonal antibodies
againstp16INK4A protein.ThespeciﬁcityofantibodieswasprovenbytheimmunostainingofHPV-transformedcells.Inconclusion,
the current study demonstrates the potential of pseudotype VLPs with inserted target antigen as a new type of immunogens to
generate antibodies of high diagnostic value.
1.Introduction
Gene and protein engineering provides an opportunity to
generate novel chimeric proteins with desired features, such
asenhancedimmunogenicity.Structuralproteinsoriginating
from human and animal viruses, for example, papilloma,
hepatitis B, and parvo- and rotaviruses with their intrinsic
capacity to self–assemble to highly organized structures—
virus-like particles (VLPs)—have been shown to possess
high immunogenicity and therefore exploited as poten-
tial vaccines [1–3]. Moreover, recombinant VLPs can be
employed as carriers for non immunogenic proteins or
peptides in order to enhance their immunogenicity. Previous
studies demonstrated that insertions/fusions of foreign pro-
tein segments at certain sites of VLP carriers derived from
papilloma-, polyoma-, hepadna-, parvo-, and retroviruses
did not inﬂuence protein folding and assembly of chimeric
VLPs. The immunogenicity of foreign sequences presented
on the surface of chimeric VLPs is enhanced making these
VLPs promising vaccine candidates [4–7]. Recently, we have
demonstrated that hamster polyomavirus (HaPyV) major
capsid protein VP1-derived VLPs are highly immunogenic
and tolerate inserts of diﬀerent size and origin at cer-
tain surface-exposed positions. The chimeric HaPyV-VP1
VLPs have been shown to activate eﬃciently the antigen-
presenting cells and induce strong insert-speciﬁc B- and T-
cell responses in mice [8, 9]. These studies demonstrated
that chimeric VLPs represent promising novel immunogens
to generate monoclonal antibodies (MAbs) of the desired
epitope-speciﬁcity. The main advantage of chimeric VLPs2 The Scientiﬁc World Journal
over tradicional immunogens such as synthetic peptides
chemically coupled to carrier proteins is the exposure of
the target sequence on the surface of VLPs thus allow-
ing its accessibility to the B cells [9]. Although chimeric
VLPs tolerate inserts up to 120 amino acid (aa) residues,
the insertion of longer protein sequences generally aﬀects
proper folding and self-assembly of VLPs (our unpublished
observation). Therefore, new approaches for enhancing the
immunogenicity of long protein segments or full-length
proteins are needed. This is especially important for human
cellular proteins that may be tolerogenic in mice because
of high homology with murine proteins. Strong immuno-
gens presenting the target protein sequence on a suitable
carrier may break the tolerance barrier and increase the
immunogenicity of non-immunogenic proteins or protein
segments.
In the current study, we designed novel recombinant
immunogens based on pseudotype VLPs consisting of two
HaPyV-derived capsid proteins—an intact VP1 protein
and modiﬁed VP2 protein harbouring the target protein
sequence at VP2 N terminus. As a target sequence, we have
used full-length cellular protein of high diagnostic relevance
p16INK4A that is considered to be a potential marker for cells
transformed by high-risk human papillomavirus (HPV). We
have demonstrated that pseudotype VLPs consisting of an
intact VP1 protein and VP2 protein fused with the p16INK4A
antigen at its N terminus induced a strong antibody response
against the target sequence which allowed generation of
p16INK4A-speciﬁc MAbs.
2.MaterialsandMethods
2.1. Production of Pseudotype VLPs Harbouring Full-Length
p16INK4A Protein. All DNA manipulations were carried out
according to standard procedures [10]. Enzymes and kits for
DNA manipulations were purchased from Thermo Scientiﬁc
Fermentas (Vilnius, Lithuania). Recombinant plasmids were
screened in E.coli DH10B cells. The synthetic gene encoding
the full length p16INK4A protein (synthesized by Integrated
DNA Technologies, BVBA, Leuven, Belgium) was fused to
hamster polyomavirus (HaPyV) VP2 gene modiﬁed at its N
terminus in the plasmid pFGG3-VP1/VP2Bg. This plasmid
was constructed by inserting HaPyV VP1 gene into GAL 7
expression cassette and modiﬁed HaPyV VP2 gene under
GAL10-PYK1 hybrid promoter into yeast expression vector
pFGG3[11].ToconstructthemodiﬁedHaPyVVP2gene,the
sequence encoding 1–100aa was deleted and GSS linker cod-
ing sequence and the BglII restriction site were introduced
at its N terminus for a fusion with p16INK4A coding sequence.
TheresultingplasmidpFGG3-VP1/VP2-p16wasusedforthe
transformation of the Saccharomyces cerevisiae strain AH22-
214 (a, leu2-3, 112, his4-519). Transformed yeast cells were
g r o w ni nY E P Dm e d i u m( y e a s te x t r a c t1 % ,p e p t o n e2 % ,
and glucose 2%) supplemented with 5mM formaldehyde
at 30◦C. The production of the recombinant protein was
induced after 24h of cultivation by adding galactose until
3% ﬁnal concentration. After 18h growth the yeast cells were
harvested by centrifugation and stored at −20◦C until use.
The expression of recombinant VP1 and VP2 proteins was
veriﬁed by gel electrophoresis and Western blot analysis of
the yeast cell lysate as decribed hereinafter.
2.2. Puriﬁcation and Electron Microscopy Analysis of Pseudo-
type VLPs. S. cerevisiae yeast biomass harbouring recombi-
nant proteins was resuspended and homogenized in DB 450
buﬀer (450mM NaCl, 1mM CaCl2, 0.001% Trition X-100,
0.25M L-Arginine in 10mM Tris/HCl-buﬀe r ,p H7 . 2 )c o n -
taining 2mM phenylmethylsulfonyl ﬂuoride (PMSF) and
EDTA-free Complete Protease Inhibitor Cocktail (Thermo
Scientiﬁc Fermentas) and mechanically disrupted using
French press. After centrifugation, the supernatant was
collected and loaded onto a 20–60% sucrose gradient. After
centrifugation at 25,000rpm (Rotor SW28, Beckman, USA)
overnight the fractions of 0.5mL were collected and sub-
jected to SDS-PAGE. The fractions containing proteins of 42
and 45kDa corresponding to VP1 and p16INK4A fused with
VP2 (VP2-p16INK4A), respectively, were pooled and diluted
in buﬀer DB 150 (150mM NaCl, 1mM CaCl2 and 0.001%
Trition X-100 in 10mM Tris/HCl-buﬀer pH 7.2). The
mixture was subjected to ultracentrifugation overnight at
100,000×g (Beckman) on CsCl gradient with densities from
1.23 to1.42g/mL. The collected fractions were analyzed as
described previously. As recombinant VP1 and VP2-
p16INK4A proteins were almost identical according to their
molecular mass, the presence of VP2-p16INK4A protein was
veriﬁed by Western blot using in-house produced murine
polyclonal antibodies against VP2 protein. Fractions con-
taining VP1/VP2-p16INK4A p r o t e i nw e r ed i l u t e da n dp r e -
cipitated by ultracentrifugation for 4h, then dissolved in
phosphate buﬀered saline (PBS), and dialyzed against PBS.
The dialyzed VP1/VP2-p16INK4A protein was aliquoted and
lyophilized.
The VLP formation was veriﬁed by examination of the
puriﬁed proteins by Morgagni 268 electron microscope (FEI
Inc., Hillsboro, OR, USA). Protein samples were placed
on 400-mesh carbon-coated palladium grids and negatively
stained with 2% aqueous uranyl acetate.
2.3. Production of GST-Fused p16INK4A Protein. To produce
p16INK4A protein fused to glutathione S-transferase (GST)
in E.coli, the DNA sequence encoding p16INK4A protein was
cloned into the expression vector pGEX-5x (Amersham).
The resulted plasmid pGEX-5x-p16 was used to transform
E.coli strain BL1. The expression of GST-fused p16INK4A
protein was conﬁrmed by SDS-PAGE and Western blot
analysis with anti-GST antibodies (GE Healthcare, Uppsala,
Sweden). The GST-p16INK4A-fused protein was puriﬁed
using Glutathione Sepharose 4 Fast Flow (GE Healthcare
Bio-Sciences AB SE-751 84) following the manufacturer’s
recommendations.
2.4. Immunization of Mice and Generation of Monoclonal
Antibodies. BALB/c mice (obtained from a breeding colony
at the Department of Immunology of the Center for
Innovative Medicine, Vilnius, Lithuania) were immunized at
days 0, 28, and 56 by a subcutaneous injection of 50µgo f
either recombinant pseudotype VLPs harbouring p16INK4A
protein or puriﬁed GST-p16INK4A-fused protein. For anThe Scientiﬁc World Journal 3
initial immunization, the antigen was emulsiﬁed in complete
Freund adjuvant (Sigma). Subsequent immunizations were
performed without an adjuvant, with the antigen dissolved
in PBS. Antisera were collected two weeks after the second
injection and tested for the presence of antibodies speciﬁc
to p16INK4A protein. The mouse with the highest antibody
titer against pseudotype VLPs was selected for the devel-
opment of MAbs. Hybridomas were generated essentially
as described by Kohler and Milstein [12] .T h r e ed a y sa f t e r
the ﬁnal injection, mouse spleen cells were fused with
Sp2/0-Ag 14 mouse myeloma cells using polyethylene glycol
1500 (PEG/DMSO solution, HybriMax, Sigma). Hybrid
cells were selected in growth medium supplemented with
hypoxantine, aminopterin, and thymidine (50x HAT media
supplement, Sigma-Aldrich, St. Louis, USA). Samples of
supernatant from wells with viable clones were screened by
an indirect enzyme-linked immunosorbent assay (ELISA)
using recombinant VLPs and GST-fused p16INK4A protein
as described hereinafter. Hybridomas secreting speciﬁc anti-
bodiestop16INK4A proteinweresubclonedtwicebyalimiting
dilution assay. Hybridoma cells were maintained in complete
Dulbecco’s modiﬁed Eagle’s medium (DMEM, Biochrom)
containing 15% fetal calf serum (Biochrom) and antibiotics.
Antibodies in hybridoma culture supernatants were isotyped
using the Mouse Monoclonal Antibody Isotyping kit (ISO-
2, Sigma) in accordance with the manufacturer’s protocol.
All procedures involving experimental mice were performed
under controlled laboratory conditions in strict accordance
with the Lithuanian and European legislation.
2.5. SDS-PAGE. Proteins were analysed by electrophoresis
on 12.5% sodium dodecylsulfate-polyacrylamide gels (SDS-
PAGE) followed by Coomassie brilliant blue staining. The
SDS-PAGEsamplebuﬀer(ThermoScientiﬁcFermentas)was
added to the prepared protein samples, boiled for 5min,
applied to a polyacrylamide gel, and run in SDS-Tris-
glycine buﬀer. Protein bands were visualized by staining with
Coomassie brilliant blue (Sigma).
2.6. Western Blot Analysis. The proteins were separated by
SDS-PAGE and electrotransferred to Immobilon P mem-
brane (Millipore). The membranes were blocked with 5%
milk in PBS for 2h at room temperature (RT). The mem-
branes were then incubated for 1h at RT with primary anti-
bodies at working dilution and subsequently incubated with
goat antimouse IgG conjugated to horseradish peroxidase
(HRP) (Bio-Rad) diluted 1:2000 in PBS with 0.1% Tween
20 (PBST). The enzymatic reaction was developed using
tetramethylbenzidine (TMB) ready-to-use chromogenic sub-
strate (Sigma). As primary antibodies for the identiﬁcation
of VP1/VP2-p16INK4A proteins, mouse MAb against HaPyV
VP1, clone 3D10 [9], and polyclonal antibodies produced
in-house against HaPyV VP2 protein were used (dilution
1:1000 in PBST). For analysing MAb speciﬁcity, undiluted
hybridoma supernatants were used.
2.7. Indirect ELISA. Polystyrene microtiter plates (Nerbe)
were coated with 100µl/well of the antigen diluted in coating
buﬀer (0.05M sodium carbonate, pH 9.6) to a concentration
of 5µg/mL by incubation overnight at 4◦C. The coated plates
were blocked with 150µL/well of 1% BSA for 2h at RT.
Plates were rinsed twice with PBST. Antiserum samples or
hybridoma growth medium were diluted in PBST, added
to the wells, and incubated for 1h at RT. The plates were
rinsed 3 times with PBST and incubated for 1h with HRP-
conjugated goat antimouse IgG (Bio-Rad) diluted 1:2000
in PBST. The plates were rinsed 5 times with PBST. The
enzymatic reaction was visualized by the addition of 100µL
of ready-to-use TMB substrate (Sigma) to each well. After
10min of incubation at RT, the reaction was stopped by
adding 50µL/well of 10% sulphuric acid. The optical density
(OD) was measured at 450nm (reference ﬁlter 620nm) in a
microplate reader (Tecan, Groedig, Austria).
2.8. Immunohistochemistry Analysis. Immunohistochemical
staining was performed on paraﬃn-embedded samples
of cervical squamous cell carcinomas and nonneoplastic
cervicaltissueselectedfromarchivalmaterialsattheNational
Specialized Hospital for Active Treatment in Oncology,
Soﬁa, Bulgaria. Haematoxylin and eosin-stained slides of all
sampleswerereviewedbyapathologistandtheirhistopatho-
logical diagnoses were reconﬁrmed. Sections (approxi-
mately 5µm thick) were cut and mounted on poly-l-lysine
coated microscope slides (Thermo Scientiﬁc). Samples were
deparaﬃnized in xylene and rehydrated in graded alcohols.
Antigen retrieval was performed in 0.01M citrate buﬀer
(pH 6.0) in a heating bath for 20min at 97◦C. Endogenous
peroxidase activity was blocked by incubating the sections in
3% H2O2 for 5min. After blocking the nonspeciﬁc binding
with 3% BSA in PBS for 3h at RT, slides were incubated with
the primary antibody (mouse polyclonal antibody raised
against pseudotype VLPs harbouring p16INK4A protein;
1:300, or mouse polyclonal antibody raised against GST-
p16INK4A fused protein; 1:100) and left overnight in moist
chambers at 4◦C. The bound antibody was visualized using a
biotinylatedsecondaryantibody,peroxidase-labelledstrepta-
vidin, and DAB substrate-chromogen (LSAB2 System-HRP,
Dako, Denmark) according to the manufacturer’s protocol.
Sections were counterstained in hematoxylin, mounted and
analyzed under light microscopy. As a negative control,
irrelevant mouse polyclonal antibody raised against yeast-
expressed hPIV3 nucleocapsid protein was used [13].
2.9. Flow-Cytometry. Adherent human cervical epithelial
HeLa cells (ATCC Cat. No. CCL-2) were cultivated in
RPMI-1640 growth medium (Biochrom, Berlin, Germany)
supplemented with 10% fetal bovine serum (Biochrom)
and antibiotics. The cells were grown at 37◦C and 5% CO2
to approximately 70% conﬂuence, harvested, resuspended
in Fixation/Permeabilization solution (BD Biosciences,
Franklin Lakes, USA), and incubated for 20 minutes at
4◦C. The cells were washed two times with BD Perm/Wash
buﬀer (BD Biosciences) and transferred to plastic tubes
for immunoﬂuorescent staining, 106 cells per test. One
hundred µLo fB DP e r m / W a s hb u ﬀer containing 5µg/mL
of the MAb against p16INK4A or appropriate positive and
negative controls were added to the cells and incubated
at 4◦C for 30min. As a positive control, commercial4 The Scientiﬁc World Journal
anti-CDK2A/p16INK4A MAb, clone DCS-50.1/H4 (Abcam,
Cambridge, UK) was used (10µg/mL). As a negative control,
irrelevant MAb of IgG1 isotype against yeast-expressed
hPIV3 nucleocapsid protein was used (10µg/mL) [13].
After incubation, the cells were washed two times with BD
Perm/Wash buﬀer and then incubated for 30min at 4◦Ci n
the dark with 50µLo fB DP e r m / W a s hb u ﬀer containing a
predetermined optimal concentration of FITC-conjugated
goat antimouse IgG (BD Pharmingen, Franklin Lakes, USA).
Finally, the cells were washed two times with BD Perm/Wash
buﬀer and resuspended in Staining Buﬀer (BD Pharmingen)
prior to ﬂow cytometric analysis. Cells were analyzed with
CyFlowRspace ﬂow cytometer (Partec, Muenster, Germany).
Not less than 20.000 events per test were evaluated with
FloMax 2.7 software.
3. Results
Full-length human p16INK4A protein (16kDa, 133aa-long)
was selected as a target protein for the generation of
pseudotype VLPs and further immunization experiments.
The alignment of aa sequences of human and murine
p16INK4A proteins using ClustalLW and BLAST computer
programs revealed 75% sequence homology (Figure 1). High
number of identical and similar aa residues indicated the low
immunogenicity of human p16INK4A in mice; therefore, the
antigen was considered to be suitable as a target sequence for
presenting on pseudotype VLPs.
For the construction of expression plasmids, synthetic
gene encoding full-length p16INK4A sequence was inserted
into yeast expression vector pFGG3-VP1/VP2Bg designed
for the coexpression HaPyV VP1 protein together with VP2
protein truncated until the 101aa residue. The resulted
plasmid pFGG3-VP1/VP2-p16 was used to transform yeast
S.cerevisiae strain AH22-214. The SDS-PAGE analysis of
crude lysates of transformed yeast cells revealed an over-
lapping protein band of approximately 42–45kD because
the molecular mass of full-length VP1 protein and VP2-
p16INK4A fused protein was very similar (42 and 45kD, resp.)
(Figure 2(a), lane 2). The corresponding protein band was
not visible in the lysate of yeast cells transformed with empty
vector pFGG3 used as a negative control (Figure 2(a),l a n e
1). Protein bands representing the VP1 protein and VP2-
p16INK4A fused protein were speciﬁcally immunostained
with the respective antibodies against HaPyV VP1 and VP2
proteins (Figures 2(b) and 2(c),l a n e2 ) .T h es o l u b l ef r a c t i o n
of the lysate of transformed yeast cells was subjected to
ultracentrifugation in sucrose and CsCl density gradients.
The puriﬁed recombinant VP1/VP2-p16INK4A proteins were
analyzed by SDS PAGE and Western blot. According to SDS-
PAGE data, the purity of VP1/VP2-p16INK4A proteins after
the ultracentrifugation step was about 99% (Figure 2(a),
lane 4). The identity of puriﬁed proteins was conﬁrmed by
Western blot analysis using speciﬁc antibodies (Figures 2(b)
and2(c),lane4).Electronmicroscopyanalysisofthepuriﬁed
negativelystainedVP1/VP2-p16INK4A proteinsconﬁrmedthe
formation of VLPs of about 45nm in diameter (Figure 2(d))
similar in their size and shape to the nonmodiﬁed VP1/VP2
VLPs (Figure 2(e)) and to native viral capsids.
Human
Mouse
Human
Mouse
Human
Mouse
Human
Mouse
Figure 1: Alignment of aa sequences of human and murine
p16INK4A using ClustalLW computer program. Identical and similar
aa residues are marked by asterisks and dots, respectively.
The pseudotype VLPs were used to immunize BALB/c
mice to generate antibodies against the inserted target
sequence. In parallel, the BALB/c mice were immunized with
puriﬁedGST-fusedp16INK4A protein.After2immunizations,
the titers of antibodies speciﬁc to VP1/VP2-p16INK4A deter-
mined by an indirect ELISA in the sera of mice immunized
with pseudotype VLPs ranged from 1:16000 to 1:32000
(data not shown). To conﬁrm the speciﬁcity of the antisera
with p16INK4A protein, their speciﬁcity was analyzed by
Western blot using fused protein GST-p16INK4A expressed in
E.coli. Speciﬁc immunostaining of GST-p16INK4A fuse was
observed, which conﬁrms that the antibodies raised against
pseudotype VLPs recognize the p16INK4A sequence (data
not shown). In contrast, the antisera raised against GST-
p16INK4A fused protein recognized only the antigen used for
immunization (titers after 2 immunizations ranged 1:4000–
1:12000) and did not show any reactivity with the p16INK4A
sequence displayed on VLPs (data not shown).
To investigate the reactivity of the antisera with cellular
p16INK4A protein, they were applied to the immunohisto-
chemistry analysis (IHC) of cervical tissue specimens. The
antisera raised against pseudotype VLPs showed speciﬁc
immunostaining of malignant cervical tissue containing
HPV-transformed cells and did not react with nonneoplastic
cervical tissue (Figure 3). This demonstrates the reactivity of
the antisera raised against pseudotype VLPs with the cellular
p16INK4A protein present in malignant cervical tissue. In
contrast, the antisera raised against GST-fused p16INK4A
protein did not show any reactivity in IHC (data not shown).
Therefore, no further experiments with mice immunized
with GST-p16INK4A fused protein were performed.
Spleen cells of mice immunized with pseudotype VLPs
were used to generate the MAbs against p16INK4A protein.
Three stable hybridoma cell lines producing p16INK4A-
speciﬁc MAbs of IgG isotype (IgG1 subtype) were generated.
The MAbs reacted speciﬁcally in Western blot both with
pseudotype VP1/VP2-p16INK4A VLPs and GST-p16INK4A fuse
but did not react either with yeast cell lysate or nonmodiﬁed
VP1/VP2 VLPs used as a negative control (Figure 4). To
prove the reactivity of the MAbs with native intracellular
p16INK4A protein,theywereappliedtoﬂow-cytometryanaly-
sis of HeLa cells that represent HPV-18–transformed cervicalThe Scientiﬁc World Journal 5
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Figure 2: Analysis of the expression of VP1/VP2-p16INK4A pseudotype VLPs in yeast. (a) Coomassie blue-stained SDS-PAGE. (b) Western
blot with the MAb 3D10 against VP1 protein. (c) Western blot with polyclonal antibody against VP2 protein. The same samples were run on
each gel. In lanes, there are (1) negative control sample from crude lysate of S. cerevisiae cells transformed with the empty vector pFGG3, (2)
crude lysate of yeast transformed with pFGG3-VP1/VP2-p16 plasmid, (3) the soluble fraction recovered after centrifugation of crude lysate
of yeast transformed with pFGG3-VP1/VP2-p16 plasmid, (4) VLPs consisting of VP1 protein and fusion protein VP2-p16 puriﬁed using
sucrose and CsCl gradients, (5) VLPs consisting of VP1 protein and nonmodiﬁed VP2 protein puriﬁed using sucrose and CsCl gradients,
and (6) prestained protein molecular mass marker (Thermo Scientiﬁc Fermentas). (d and e) Electron microscopy pictures of VP1/VP2-
p16INK4A (d) and nonmodiﬁed VP1/VP2 (e) pseudotype VLPs, stained with 2% aqueous uranyl acetate solution and examined by Morgagni
268 electron microscope.
epithelial cells. The intracellular staining of HeLa cells con-
ﬁrmed the ability of the MAbs to recognize the intracellular
native p16INK4A a n dr ev e a l e da b o u t6 5 %o fp 1 6 INK4A-positive
cells (Figure 5(a)). The positivity of HeLa cells for p16INK4A-
proteinwasconﬁrmedbytheirspeciﬁcimmunostainingwith
the commercial MAb against p16INK4A protein (Figure 5(b)).
No speciﬁc immunostaining of HeLa cells was observed
with an irrelevant MAb of the same isotype (Figure 5(c)).
Thus, polyclonal and monoclonal antibodies raised against
pseudotype VLPs harbouring the full-length p16INK4A
sequence were reactive with cellular native p16INK4A protein.
This is an indirect evidence that the p16INK4A molecule dis-
played on the surface of pseudotype VLPs is natively folded.
In conclusion, our results demonstrate that pseudotype
VLPs represent highly eﬃcient carrier for cellular antigens
and elicit a strong antibody response against the target pro-
tein presented on the surface of VLPs.
4. Discussion
The aim of the current study was to design novel recom-
binant antigen capable to display surface-exposed foreign
protein sequences and enhance their immunogenicity. Such
recombinant antigens may be applied for the generation of
antibodies against cellular proteins of low immunogenicity.
As a target protein for the construction of the recombinant
antigen, we have selected the cellular marker p16INK4A that
represents an indirect indicator of cell cycle dysregulation
associated with high-risk HPV infection. The expression
of p16INK4A is speciﬁcally induced in HPV-infected cells
by HPV E7 protein that inactivates regulatory protein pRb
(retinoblastoma gene product) and upregulates transcription
factor E2F, which allows the cdk gene transcription. The
product of cdk gene is protein p16INK4A. Several stud-
ies examined the p16INK4A protein by immunocytochem-
ical analysis and conﬁrmed its diagnostic relevance as a
biomarker for dysplastic squamous and glandular cells of the
cervix [14–16].
Based on the alignment of aa sequences of human
and murine p16INK4A proteins that revealed high degree of
homology, the low immunogenicity of human p16INK4A in
mice was predicted. To enhance its immunogenicity, we have
constructed pseudotype VLPs consisting of an intact HaPyV
VP1 protein and VP2 protein fused with the target antigen—
p16INK4A protein—at VP2 N terminus. Both recombinant
proteins coexpressed in yeast S.cerevisiae were able to self-
assemble to pseudotype VLPs harbouring the inserted target
antigen. The shape and size of the pseudotype VLPs was
similar to that observed for the native HaPyV capsids [17].
From the resolved crystal structures of the virions of SV-40
[18] and murine polyomavirus [19] it is known that the
capsid of polyomaviruses mainly consists of 72 pentamers6 The Scientiﬁc World Journal
(a) (b)
Figure 3: Immunohistochemical analysis of cervical tissues using mouse polyclonal antibody raised against pseudotype VLPs harbouring
the p16INK4A protein. (a) Invasive squamous cell carcinoma; (b) nonneoplastic cervical tissue (condyloma).
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Figure 4:ThereactivityoftheMAbsraisedagainst VP1/VP2-p16INK4A pseudotypeVLPswiththep16INK4A protein sequence in Western blot.
(a) Coomassie blue-stained SDS-PAGE. (b–d) Western blot with the MAbs raised against pseudotype VLPs, clones 9F12 (b), 11E12 (c), and
26D11 (d). Lane M: prestained protein molecular mass marker (Thermo Scientiﬁc Fermentas); lane 1: puriﬁed GST-fused p16INK4A protein;
lane 2: puriﬁed pseudotype VP1/VP2-p16INK4A VLPs; lane 3: puriﬁed nonmodiﬁed VP1/VP2 VLPs; lane 4: crude lysate of nontransformed
S. cerevisiae cells.
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Figure 5: Flow-cytometry analysis of HeLa cells immunostained with the MAbs: (a) clone 9F12 (IgG1 subtype) raised against pseudotype
VLPs harbouring the p16INK4A protein; (b) negative control, irrelevant Mab of IgG1 subtype; (c) positive control, commercial MAb against
p16INK4A protein (Abcam).The Scientiﬁc World Journal 7
formed by 360 copies of the VP1 protein. One minor capsid
protein, either VP2 or VP3, binds in the central 5-fold cavity
of each VP1 pentamer [20]. The C terminal part of VP2
protein is necessary for it interaction with VP1 pentamer
[20]; therefore, we have used the VP2 N-terminus to join
the full-length p16INK4A molecule. The ratio of VP1:VP2
proteins in HaPyV capsid is 360:72 [20]; consequently up to
72 chimeric VP2-p16 molecules might be incorporated into
oneVLP.Itwassupposedthattheinsertedp16INK4A sequence
will be displayed on the surface of pseudotype VLPs thus
allowing its accessibility to the B cells. The immunogenicity
of pseudotype VLPs in mice was proven by immunization
experiments and subsequent generation of p16INK4A-speciﬁc
MAbs. Polyclonal antibodies raised against pseudotype VLPs
speciﬁcally recognized p16INK4A sequence both by Western
blot using recombinant E.coli-expressed GST-p16INK4A fuse
and by the immunohistochemistry using cervical tissue
specimens. In contrast, the immunization of mice with the
same doses of GST-fused p16INK4A protein did not induce
formation of p16INK4A-speciﬁc antibodies, most likely due to
the masking of the target sequence by the GST. The immu-
nization of mice with pseudotype VLPs allowed generation
of several MAbs that speciﬁcally recognized recombinant
p16INK4A protein by both ELISA and Western blot. Moreover,
the reactivity of the MAbs with the intracellular native
p16INK4A was demonstrated. The ability of the MAbs to
recognize native cellular p16INK4A suggests proper folding of
the target sequence displayed on the surface of pseudotype
VLPs. The obtained results demonstrate the eﬃciency of
pseudotype VLPs in presenting foreign protein sequences to
B cells for the generation of target-speciﬁc antibodies.
5. Conclusions
Hamster polyomavirus-derived proteins VP1 and VP2 capa-
ble to self-assemble to VLPs can be employed to construct
chimeric proteins with improved immunogenicity. Yeast-
expressed pseudotype VLPs consisting of the intact VP1
protein and VP2 protein fused to the cellular antigen
p16INK4A are immunogenic and induce antibodies speciﬁc to
the p16INK4A sequence. The current study demonstrates the
potential of pseudotype VLPs with inserted target antigen as
a new type of immunogens to generate antibodies of high
diagnostic relevance.
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